Paul A Frohna (Paul Frohna)

Publication Activity (10 Years)

Years Active: 2019-2021
Publications (10 Years): 2

Top Topics

Combination Therapy

Dendritic Cells

Immune Response

Top Venues

Journal of clinical pharmacology

Science translational medicine

Bioniz Therapeutics, Inc.

University of Pennsylvania Perelman School of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Bioniz Therapeutics, Inc. Dec 19 2016

United States

Chief Medical Officer

Receptos, Inc. Dec 04 2013 - Oct 01 2016

United States

Vice President, Clinical Development & Translational Medicine :: Clinical Development & Translational Medicine

Education History

University of Pennsylvania Perelman School of Medicine Jun 04 1990 - Dec 20 1995

United States

PHD :: Pharmacology

Publications

Aude De Gassart, Kieu-Suong Le, Patrick Brune, Sophie Agaugué, Jennifer Sims, Armelle Goubard, Rémy Castellano, Noémie Joalland, Emmanuel Scotet, Yves Collette, Emmanuel Valentin, Clement Ghigo, Christine Pasero, Magali Colazet, Jaime Guillén, Carla E Cano, Aurélien Marabelle, Johann S de Bono, René Hoet, Alemseged Truneh, Daniel Olive, Paul A Frohna
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response. Science translational medicine 13 (616) (2021)
Paul A Frohna, Anoshie Ratnayake, Nick Doerr, Asjad Basheer, Laith Q Al-Mawsawi, Woo Jae Kim, Juan C Zapata, Xiaorong Wu, Thomas A Waldmann, Nazli Azimi, Yutaka Tagaya
Results From a First-in-Human Study of BNZ-1, a Selective Multicytokine Inhibitor Targeting Members of the Common Gamma (γc) Family of Cytokines. Journal of clinical pharmacology 60 (2) (2019)